In early November, ADC Therapeutics SA made headlines by announcing it would not file for accelerated approval of camidanlumab tesirine for Hodgkin’s lymphoma in 2023 because the US Food and Drug Administration provided “strong guidance” that a randomized, confirmatory study must be well underway, and ideally fully enrolled, at the time of application submission.
US FDA Has History Of Pushing Sponsors On Confirmatory Trials … Sometimes
Even before a new law granted FDA authority to require studies be underway before accelerated approval, review divisions have, in some cases, given sponsors years of advance notice on expectations around study timing, according to a Pink Sheet review of NME accelerated approvals.
More from Pink Sheet Perspectives
More from Pink Sheet
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.